- Home
- CABA vs VXRT Comparison
CABA vs VXRT Comparison
Compare CABA & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- VXRT
- Stock Information
- Founded
- CABA 2017
- VXRT N/A
- Country
- CABA United States
- VXRT United States
- Employees
- CABA N/A
- VXRT N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CABA Health Care
- VXRT Health Care
- Exchange
- CABA Nasdaq
- VXRT Nasdaq
- Market Cap
- CABA 210.0M
- VXRT 200.3M
- IPO Year
- CABA 2019
- VXRT N/A
- Fundamental
- Price
- CABA $3.03
- VXRT $0.58
- Analyst Decision
- CABA Strong Buy
- VXRT Strong Buy
- Analyst Count
- CABA 10
- VXRT 2
- Target Price
- CABA $28.50
- VXRT $3.00
- AVG Volume (30 Days)
- CABA 1.1M
- VXRT 1.5M
- Earning Date
- CABA 11-14-2024
- VXRT 11-13-2024
- Dividend Yield
- CABA N/A
- VXRT N/A
- EPS Growth
- CABA N/A
- VXRT N/A
- EPS
- CABA N/A
- VXRT N/A
- Revenue
- CABA N/A
- VXRT $16,760,000.00
- Revenue This Year
- CABA N/A
- VXRT $67.95
- Revenue Next Year
- CABA N/A
- VXRT N/A
- P/E Ratio
- CABA N/A
- VXRT N/A
- Revenue Growth
- CABA N/A
- VXRT 303.27
- 52 Week Low
- CABA $2.96
- VXRT $0.52
- 52 Week High
- CABA $26.35
- VXRT $1.54
- Technical
- Relative Strength Index (RSI)
- CABA 32.06
- VXRT 24.96
- Support Level
- CABA $4.33
- VXRT $0.67
- Resistance Level
- CABA $4.49
- VXRT $0.75
- Average True Range (ATR)
- CABA 0.38
- VXRT 0.05
- MACD
- CABA -0.07
- VXRT -0.01
- Stochastic Oscillator
- CABA 3.91
- VXRT 0.04
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.